WUHN Stock Overview
Through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Wuhan General Group (China), Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0002 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 11 Month Change | -99.00% |
| 3 Month Change | n/a |
| 1 Year Change | -99.00% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| WUHN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 2.8% | 1.0% |
| 1Y | -99.0% | 13.3% | 31.4% |
Return vs Industry: WUHN underperformed the US Pharmaceuticals industry which returned 13.3% over the past year.
Return vs Market: WUHN underperformed the US Market which returned 31.4% over the past year.
Price Volatility
| WUHN volatility | |
|---|---|
| WUHN Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: WUHN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine WUHN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | n/a | Jeff Robinson | wuhn.org |
Wuhan General Group (China), Inc., through its subsidiaries, researches, develops, and commercializes a range of cannabidiol (CBD)-based products under the Dr. AnnaRx brand for pharmacies. It also focuses on exploring and developing other indications for psilocybin new therapies that will enable patients who suffer from mental illness. The company offers its products for medical applications, including cancer, mental disorders, chronic pain, and others.
Wuhan General Group (China), Inc. Fundamentals Summary
| WUHN fundamental statistics | |
|---|---|
| Market cap | US$55.00 |
| Earnings (TTM) | -US$10.61m |
| Revenue (TTM) | US$80.38m |
0.0x
P/S Ratio0.0x
P/E RatioIs WUHN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| WUHN income statement (TTM) | |
|---|---|
| Revenue | US$80.38m |
| Cost of Revenue | US$65.84m |
| Gross Profit | US$14.54m |
| Other Expenses | US$25.15m |
| Earnings | -US$10.61m |
Last Reported Earnings
Dec 31, 2012
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did WUHN perform over the long term?
See historical performance and comparison